Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06440980 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 533
- Enrollment target
NCT06440980 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 533 participants.
The verdict
NCT06440980, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 533 participants
- Enrollment target
Study Summary
The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.
Interventions
- DRUG Orforglipron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 533 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2025-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06440980
The ClinicalTrials.gov registry entry for NCT06440980 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 533 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Orforglipron is the first listed.
NCT06440980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06440980 about?
NCT06440980 is a clinical study titled "A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight". The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron...
What is the current status of trial NCT06440980?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 533 participants. The study started on 2024-06-24. Estimated completion is 2025-06-02.
What interventions are being tested in trial NCT06440980?
The interventions under investigation include: Orforglipron (DRUG).
Who is sponsoring clinical trial NCT06440980?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.